Publications by authors named "G S Germain"
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with exacerbations which can reduce quality of life and increase mortality. Single-inhaler triple therapy (SITT) is recommended for maintenance treatment of COPD among patients experiencing exacerbations despite dual-therapy use. This real-world comparative effectiveness study compared the impact of SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), and budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), on COPD exacerbations and mortality.
View Article and Find Full Text PDFIntroduction: The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β-agonist (ICS/LABA).
View Article and Find Full Text PDFArticle Synopsis
- This study examines how well patients with chronic obstructive pulmonary disease (COPD) stick to their medication regimens, comparing a single daily inhaler (FF/UMEC/VI) to a combination that requires two inhalations twice a day (BUD/GLY/FOR).
- Using insurance claims data from 2019 to 2023, researchers evaluated adherence (how often patients take their medication) and persistence (how long they continue treatment), with a total of 11,597 COPD patients involved.
- Results showed that patients using the single inhaler (FF/UMEC/VI) had better adherence and persistence over 6 and 12 months compared to those using the combination
Article Synopsis
- This study examined the impact of geographic atrophy (GA) on elderly patients with Medicare Advantage plans in the U.S., focusing on both clinical and economic aspects.
- Researchers analyzed data from 18,119 patients with GA only and compared them to 72,476 patients without GA, noting higher rates of healthcare usage and increased healthcare costs for those with GA.
- The results indicate that as GA progresses to more severe conditions like visual impairment and blindness, both the clinical complications and healthcare costs significantly increase, highlighting the need for early intervention.
Aims: To evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis.
Methods: Adults with a BP-I diagnosis (first claim = index), commercial, Medicare Supplemental, or Medicaid insurance, and ≥1 outpatient cariprazine dispensing were identified from Merative MarketScan database. Cohorts included patients who initiated cariprazine as either their first or subsequent AA after initial BP-I diagnosis.